



Respiratory


Respiratory drug development and commercialisation encompass improvements in existing classes of systemic and inhaled treatments as well as novel agents for common and rare respiratory conditions. Finding effective and safe new classes of drugs to treat asthma and COPD remains difficult. tranScrip teams have expertise in all major respiratory indications from asthma, COPD and allergy to orphan indications such as cystic fibrosis or idiopathic pulmonary fibrosis. We are helping our clients address clinical and regulatory challenges, differentiate their products and realise drug development and lifecycle goals.

Visit [transcrip-group.com](https://www.transcrip-group.com)



Diverse Programmes Effective Execution

A snapshot of our recent projects



tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle.

We build product strategies as well as design and execute development programmes and commercialisation activities.

Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts, offer truly flexible bespoke solutions and support to maximise the value of products.

We help to expedite the development and commercialisation of products for the benefit of patients worldwide.

